Earlier diagnosis of acute kidney injury awaits effective therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21566636.
- Also identified by DOI 10.1038/ki.2011.19.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Novel urinary biomarkers for the early, sensitive, and specific diagnosis of acute kidney injury (AKI) show promise for the improved management of patients with this treatment-resistant complication. Several biomarkers (Kim-1, lipocalin-2, osteopontin, gluthathione S-transferases) that were tested by Rouse et al. during gentamicin-induced AKI and its recovery possess renoprotective activities, capabilities that may guide the development of novel interventions. However, despite the increased commercial availability of biomarkers, effective therapies for clinical AKI await discovery.
Medical subject headings
- Acute Kidney Injury
- Biomarkers
- Kidney Tubules, Proximal
- Proteomics